Pharmacoeconomics: theory and practice
№2, 2014, Vol.2

Serpik V.G. 1626

Summary: The pharmacoeconomic evaluation of the treatment of infectious bacterial conjunctivitis by the medicaments of fluoroquinolones: moxifloxacin (Vigamox), levofloxacin (Oftaquix, Signicef), ciproflaxacinum (Cipromed) and ofloxacin (Floksal) have been conducted in regards to the conditions of the Russian health care system. The results of analysis of the «cost-effectiveness» have shown that the medicament of moxifloxacin (Vigamox) is dominant over the comparator medicaments, requiring the least cost to achieve the successful treatment of bacterial conjunctivitis per patient. The «budget impact» analysis have illustrated that the replacement of the fluoroquinolone medicament of the II-III generation for the moxifloxacin (Vigamox) in the treatment of bacterial conjunctivitis is accompanied by cost savings. Keywords: pharmacoeconomic studies, infectious bacterial conjunctivitis, fluoroquinolones, moxifloxacin, levofloxacin, ciprofloxacin, ofloxacin, analysis of the «cost-benefit», “budget impact» analysis.